A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Hospital tests eventually revealed that her 95-year-old mother Jane Tan (not her real name) had respiratory syncytial virus (RSV). “She couldn’t breathe at all,” recalls Ms Chua.